A paradigm shift in how we fight cancer at its molecular roots
En los laboratorios del Centro de Investigación del Cáncer de Salamanca, un equipo de científicas españolas ha encontrado un nuevo punto de vulnerabilidad en el cáncer de próstata: no en la célula tumoral en sí, sino en la maquinaria molecular que le permite sobrevivir y adaptarse. Lideradas por Sandra Blanco, estas investigadoras apuntan a las modificaciones químicas del ARN como diana terapéutica, con la esperanza de devolver eficacia a tratamientos que los tumores han aprendido a esquivar. En un país donde más de 34.000 hombres recibirán este diagnóstico solo en 2026, la pregunta que guía este trabajo no es únicamente cuánto tiempo se puede ganar, sino cómo se vive el tiempo que queda.
- El cáncer de próstata avanzado ha desarrollado una capacidad inquietante para volverse resistente a los tratamientos existentes, dejando a muchos pacientes sin opciones eficaces.
- Las enzimas RNA metiltransferasas, habitualmente alteradas o sobreactivadas en tumores humanos, emergen ahora como el eslabón débil que los investigadores quieren explotar.
- La colaboración entre la biología del cáncer de Blanco y la química orgánica computacional de Hernández permite diseñar inhibidores selectivos antes incluso de sintetizarlos, acortando el camino del laboratorio a la clínica.
- Más allá de la supervivencia, el proyecto busca reducir los efectos secundarios devastadores —incontinencia, disfunción eréctil, fatiga, pérdida ósea— que redefinen la vida cotidiana de los pacientes.
- La investigación, financiada por la Asociación Española Contra el Cáncer, apunta a un cambio de paradigma: tratar el cáncer atacando su capacidad de adaptación, no solo su presencia.
Un equipo de investigadoras españolas ha identificado un nuevo frente en la lucha contra el cáncer de próstata: las modificaciones químicas que ocurren dentro de las propias moléculas de ARN. El trabajo, liderado por Sandra Blanco desde el Centro de Investigación del Cáncer de Salamanca, propone un giro conceptual significativo, pasando de atacar directamente las células tumorales a desactivar la maquinaria molecular que permite al cáncer crecer, extenderse y resistir los tratamientos.
Blanco trabaja junto a la química Ángela Patricia Hernández, de la Universidad de Salamanca, para diseñar moléculas capaces de inhibir selectivamente las RNA metiltransferasas, enzimas que regulan procesos celulares clave en la progresión tumoral. Estas enzimas aparecen frecuentemente alteradas en cánceres humanos, lo que explicaría por qué algunos pacientes desarrollan resistencia a las terapias convencionales. El objetivo es doble: frenar el avance del tumor y restaurar la sensibilidad a los fármacos ya existentes.
La dimensión humana del proyecto es inseparable de su ambición científica. El cáncer de próstata es el más diagnosticado entre los hombres españoles, con cerca de 35.000 nuevos casos previstos en 2026, y sus tratamientos actuales conllevan consecuencias que transforman profundamente la vida de quienes los padecen. Un fármaco que controle la enfermedad con menos efectos adversos no mejoraría solo las estadísticas de supervivencia, sino la experiencia real de vivir con ella.
"Nuestro objetivo es desarrollar fármacos innovadores que no solo detengan el avance de los tumores, sino que también mejoren la respuesta a los tratamientos existentes y la calidad de vida de los pacientes", ha señalado Blanco. La investigación, financiada por la Asociación Española Contra el Cáncer, representa un punto de encuentro entre el descubrimiento científico básico y una necesidad clínica urgente.
Spanish researchers have identified a new angle of attack against prostate cancer: the chemical modifications that occur within RNA molecules themselves. The work, led by Sandra Blanco at the Cancer Research Center in Salamanca, represents a shift in how scientists think about treating the disease—moving beyond the tumor cells themselves to target the molecular machinery that allows cancer to survive and adapt.
Blanco and her team, working alongside chemist Ángela Patricia Hernández from the University of Salamanca's organic chemistry department, are developing drugs that would inhibit specific enzymes called RNA methyltransferases. These enzymes regulate cellular processes tied directly to how tumors grow and spread. Recent research has shown that these same enzymes are often overactive or altered in human cancers, which helps explain why some patients develop resistance to standard treatments. By designing molecules that selectively block these enzymes, the researchers hope to not only slow tumor progression but also restore sensitivity to existing therapies.
The work carries particular weight because prostate cancer remains the most commonly diagnosed cancer among Spanish men, with an estimated 34,833 new cases expected in 2026. While survival rates have improved thanks to early detection and better drugs, the disease still ranks among the leading causes of cancer death in men. Advanced cases remain stubbornly difficult to treat. The research is funded by the Spanish Association Against Cancer and aims to address one of oncology's most pressing challenges: patients whose tumors learn to evade the drugs designed to kill them.
What makes this approach distinctive is the combination of expertise it brings together. Blanco's team brings deep knowledge of how RNA is modified in cancer cells and can test new compounds in laboratory models. Hernández's group contributes sophisticated drug design, the ability to synthesize new chemical compounds, and computational tools that allow researchers to predict how molecules will behave before they're even made. This collaboration compresses the distance between theory and testable reality.
Beyond extending survival, the research addresses a dimension of prostate cancer that often goes unspoken in clinical discussions: the toll of the disease and its treatment on daily life. Men with prostate cancer frequently contend with urinary incontinence, erectile dysfunction, fatigue, and weakened bones—consequences that reshape their physical existence and emotional wellbeing. A drug that could control the cancer while producing fewer of these side effects would represent a genuine improvement in what patients actually experience, not just in survival statistics.
Blanco has framed the work as a paradigm shift. "The potential of RNA modifications as a therapeutic target represents a fundamental change in how we fight cancer," she said. "Our goal is to develop innovative drugs that not only stop tumors from advancing, but also improve how patients respond to existing treatments and enhance their quality of life." The research sits at the intersection of basic science discovery and clinical need—identifying a vulnerability in cancer cells while keeping sight of the people living with the disease.
Citas Notables
RNA modifications as a therapeutic target represent a fundamental change in how we fight cancer. Our goal is to develop innovative drugs that not only stop tumors from advancing, but also improve how patients respond to existing treatments and enhance their quality of life.— Sandra Blanco, Cancer Research Center
La Conversación del Hearth Otra perspectiva de la historia
Why focus on RNA modifications rather than the cancer cells themselves?
Because cancer cells are constantly evolving. They learn to resist the drugs we throw at them. But the machinery that controls how RNA behaves—that's more fundamental. If we can disrupt that, we're attacking something the cancer depends on at a deeper level.
And these methyltransferase enzymes—they're overactive in prostate cancer specifically?
They're overactive in many cancers, but yes, in prostate cancer they play a significant role in progression and in helping tumors survive treatment. That's what makes them a viable target.
How long before this becomes a drug patients can actually take?
That's the honest question. We're still in the preclinical phase—testing in models, refining the compounds. Years away, likely. But the foundation is solid, and the need is urgent.
What about those side effects you mentioned—incontinence, erectile dysfunction? Can a drug targeting RNA modifications actually reduce those?
Not directly. But if we can control the cancer more effectively with lower doses or fewer rounds of treatment, patients endure less toxicity overall. That's the real-world benefit.
Is this approach unique to Spain, or are other countries working on the same thing?
The science of RNA modifications is global. But this particular collaboration, this specific focus on prostate cancer resistance—that's distinctly Spanish work, funded by Spanish cancer organizations. It matters that the research is happening here.